請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/59823
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 莊曜宇(Eric Y. Chuang) | |
dc.contributor.author | Gao-Ming Chang | en |
dc.contributor.author | 張高銘 | zh_TW |
dc.date.accessioned | 2021-06-16T09:39:49Z | - |
dc.date.available | 2017-02-16 | |
dc.date.copyright | 2017-02-16 | |
dc.date.issued | 2017 | |
dc.date.submitted | 2017-02-08 | |
dc.identifier.citation | 1. Siegel, R., Naishadham, D., and Jemal, A. (2012) Cancer statistics, 2012. CA: A Cancer Journal for Clinicians 62, 10-29
2. (2011) Department of Health, R.O.C.T. . 3. Lu, T.-P., Tsai, M.-H., Lee, J.-M., Hsu, C.-P., Chen, P.-C., Lin, C.-W., Shih, J.-Y., Yang, P.-C., Hsiao, C. K., and Lai, L.-C. (2010) Identification of a novel biomarker, SEMA5A, for non–small cell lung carcinoma in nonsmoking women. Cancer Epidemiology Biomarkers & Prevention 19, 2590-2597 4. Mulshine, J. L. (2005) New developments in lung cancer screening. Journal of Clinical Oncology 23, 3198-3202 5. Lee, B.-J., Kim, B., and Lee, K. (2014) Air pollution exposure and cardiovascular disease. Toxicological Research 30, 71-75 6. Smoke, T., and Smoking, I. (2004) IARC monographs on the evaluation of carcinogenic risks to humans. IARC, Lyon, 1-1452 7. Finkelstein, M., Kusiak, R., and Suranyi, G. (1982) Mortality among miners receiving workmen's compensation for silicosis in Ontario: 1940-1975. Journal of Occupational and Environmental Medicine 24, 663-667 8. Wu, A. H., Fontham, E. T., Reynolds, P., Greenberg, R. S., Buffler, P., Liff, J., Boyd, P., Henderson, B. E., and Correa, P. (1995) Previous lung disease and risk of lung cancer among lifetime nonsmoking women in the United States. American Journal of Epidemiology 141, 1023-1032 9. Wu, A. H., Mimi, C. Y., Thomas, D. C., Pike, M. C., and Henderson, B. E. (1988) Personal and family history of lung disease as risk factors for adenocarcinoma of the lung. Cancer Research 48, 7279-7284 10. Alavanja, M. C., Brown, C. C., Swanson, C., and Brownson, R. C. (1993) Saturated fat intake and lung cancer risk among nonsmoking women in Missouri. Journal of the National Cancer Institute 85, 1906-1916 11. De Stefani, E., Deneo-Pellegrini, H., Mendilaharsu, M., Carzoglio, J. C., and Ronco, A. (1997) Dietary fat and lung cancer: a case-control study in Uruguay. Cancer Causes & Control 8, 913-921 12. Wood, M. E., Kelly, K., Mullineaux, L. G., and Bunn, P. A. (2000) The inherited nature of lung cancer: a pilot study. Lung Cancer 30, 135-144 13. Hirayasu, T., Iwamasa, T., Kamada, Y., Koyanagi, Y., Usuda, H., and Genka, K. (1996) Human papillomavirus DNA in squamous cell carcinoma of the lung. Journal of Clinical Pathology 49, 810-817 14. Ger, L., Liou, S., Shen, C., Kao, S., and Chen, K. (1992) [Risk factors of lung cancer]. J. Formosan Med. Assoc. 91, S222-231 15. Halvorsen, A. R., Silwal-Pandit, L., Meza-Zepeda, L. A., Vodak, D., Vu, P., Sagerup, C., Hovig, E., Myklebost, O., B?rresen-Dale, A.-L., Brustugun, O. T., and Helland, Å. (2016) TP53 Mutation Spectrum in Smokers and Never Smoking Lung Cancer Patients. Frontiers in Genetics 7, 85 16. Shtivelman, E., Hensing, T., Simon, G. R., Dennis, P. A., Otterson, G. A., Bueno, R., and Salgia, R. (2014) Molecular pathways and therapeutic targets in lung cancer. Oncotarget 5, 1392-1433 17. Yoshida, A., Kohno, T., Tsuta, K., Wakai, S., Arai, Y., Shimada, Y., Asamura, H., Furuta, K., Shibata, T., and Tsuda, H. (2013) ROS1-rearranged lung cancer: a clinicopathologic and molecular study of 15 surgical cases. The American journal of surgical pathology 37, 554-562 18. Zhou, Z. h., Rao, J., Yang, J., Wu, F., Tan, J., Xu, S. l., Ding, Y., Zhan, N., Hu, X. g., and Cui, Y. h. (2015) SEMA3F prevents metastasis of colorectal cancer by PI3K–AKT‐dependent down‐regulation of the ASCL2–CXCR4 axis. The Journal of pathology 236, 467-478 19. Aplan, P. D. (2006) Causes of oncogenic chromosomal translocation. Trends in Genetics 22, 46-55 20. Luo, L. (2002) Actin cytoskeleton regulation in neuronal morphogenesis and structural plasticity. Annu. Rev. Cell. Dev. Biol. 18, 601-635 21. Lu, T. P., Tsai, M. H., Lee, J. M., Hsu, C. P., Chen, P. C., Lin, C. W., Shih, J. Y., Yang, P. C., Hsiao, C. K., Lai, L. C., and Chuang, E. Y. (2010) Identification of a novel biomarker, SEMA5A, for non-small cell lung carcinoma in nonsmoking women. Cancer Epidemiol Biomarkers Prev 19, 2590-2597 22. Girdhani, S., Bhosle, S., Thulsidas, S., Kumar, A., and Mishra, K. (2005) Potential of radiosensitizing agents in cancer chemo-radiotherapy. Journal of Cancer Research and Therapeutics 1, 129 23. Glantz, M. J., Burger, P. C., Friedman, A. H., Radtke, R. A., Massey, E. W., and Schold, S. C., Jr. (1994) Treatment of radiation-induced nervous system injury with heparin and warfarin. Neurology 44, 2020-2027 24. American Cancer Society. 25. National Institutes of Health. 26. Brizel, D. M. (2007) Pharmacologic approaches to radiation protection. Journal of Clinical Oncology 25, 4084-4089 27. Moss, R. W. (2007) Do antioxidants interfere with radiation therapy for cancer? Integrative Cancer Therapies 6, 281-292 28. Praetorius, N. P., and Mandal, T. K. (2008) Alternate delivery route for amifostine as a radio‐/chemo‐protecting agent. Journal of Pharmacy and Pharmacology 60, 809-815 29. Eberhardt, W. E., De Ruysscher, D., Weder, W., Le Pechoux, C., De Leyn, P., Hoffmann, H., Westeel, V., Stahel, R., Felip, E., and Peters, S. (2015) 2nd ESMO Consensus Conference in Lung Cancer: locally advanced stage III non-small-cell lung cancer. Ann. Oncol. 26, 1573-1588 30. Herbst, R. S., Giaccone, G., Schiller, J. H., Natale, R. B., Miller, V., Manegold, C., Scagliotti, G., Rosell, R., Oliff, I., Reeves, J. A., Wolf, M. K., Krebs, A. D., Averbuch, S. D., Ochs, J. S., Grous, J., Fandi, A., and Johnson, D. H. (2004) Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 2. Journal of Clinical Oncology 22, 785-794 31. Giaccone, G., Herbst, R. S., Manegold, C., Scagliotti, G., Rosell, R., Miller, V., Natale, R. B., Schiller, J. H., Von Pawel, J., Pluzanska, A., Gatzemeier, U., Grous, J., Ochs, J. S., Averbuch, S. D., Wolf, M. K., Rennie, P., Fandi, A., and Johnson, D. H. (2004) Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 1. Journal of Clinical Oncology 22, 777-784 32. Rosenberg, B. (1985) Fundamental studies with cisplatin. Cancer 55, 2303-l2306 33. Boulikas, T., Pantos, A., Bellis, E., and Christofis, P. (2007) Designing platinum compounds in cancer: structures and mechanisms. Journal of Cancer Therapy 5, 537-583 34. Crul, M., Schellens, J., Beijnen, J., and Maliepaard, M. (1997) Cisplatin resistance and DNA repair. Cancer Treatment Reviews 23, 341-366 35. Cohen, S. M., and Lippard, S. J. (2001) Cisplatin: from DNA damage to cancer chemotherapy. Progress in Nucleic Acid Research and Molecular Biology 67, 93-130 36. Siddik, Z. H. (2003) Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene 22, 7265-7279 37. Walker, E., and Gale, G. R. (1981) Methods of reduction of cisplatin nephrotoxicity. Annals of Clinical & Laboratory Science 11, 397-410 38. Cavalli, F., Tschopp, L., Sonntag, R., and Zimmermann, A. (1978) A case of liver toxicity following cis-dichlorodiammineplatinum (II) treatment. Cancer Treatment Reports 62, 2125 39. Micheau, O., Solary, E., Hammann, A., and Dimanche-Boitrel, M. T. (1999) Fas ligand-independent, FADD-mediated activation of the Fas death pathway by anticancer drugs. J. Biol. Chem. 274, 7987-7992 40. Capparuccia, L., and Tamagnone, L. (2009) Semaphorin signaling in cancer cells and in cells of the tumor microenvironment--two sides of a coin. J. Cell Sci. 122, 1723-1736 41. Gu, C., and Giraudo, E. (2013) The role of semaphorins and their receptors in vascular development and cancer. Exp. Cell Res. 319, 1306-1316 42. Neufeld, G., and Kessler, O. (2008) The semaphorins: versatile regulators of tumour progression and tumour angiogenesis. Nature Reviews Cancer 8, 632-645 43. Nasarre, P., Potiron, V., Drabkin, H., and Roche, J. (2010) Guidance molecules in lung cancer. Cell Adhesion & Migration 4, 130-145 44. Kruger, R. P., Aurandt, J., and Guan, K. L. (2005) Semaphorins command cells to move. Nature reviews. Molecular cell biology 6, 789-800 45. Potiron, V. A., Roche, J., and Drabkin, H. A. (2009) Semaphorins and their receptors in lung cancer. Cancer Lett. 273, 1-14 46. Law, J. W., and Lee, A. Y. (2012) The role of semaphorins and their receptors in gliomas. Journal of signal transduction 2012, 902854 47. Zhou, Y., Gunput, R. A., and Pasterkamp, R. J. (2008) Semaphorin signaling: progress made and promises ahead. Trends Biochem. Sci. 33, 161-170 48. Kagoshima, M., and Ito, T. (2001) Diverse gene expression and function of semaphorins in developing lung: positive and negative regulatory roles of semaphorins in lung branching morphogenesis. Genes to Cells 6, 559-571 49. Kawakami, T., Tokunaga, T., Hatanaka, H., Kijima, H., Yamazaki, H., Abe, Y., Osamura, Y., Inoue, H., Ueyama, Y., and Nakamura, M. (2002) Neuropilin 1 and neuropilin 2 co‐expression is significantly correlated with increased vascularity and poor prognosis in nonsmall cell lung carcinoma. Cancer 95, 2196-2201 50. Lantuéjoul, S., Constantin, B., Drabkin, H., Brambilla, C., Roche, J., and Brambilla, E. (2003) Expression of VEGF, semaphorin SEMA3F, and their common receptors neuropilins NP1 and NP2 in preinvasive bronchial lesions, lung tumours, and cell lines. The Journal of Pathology 200, 336-347 51. Nasarre, P., Potiron, V., Drabkin, H., and Roche, J. (2010) Guidance molecules in lung cancer. Cell Adhesion & Migration 4, 130-145 52. Gaur, P., Bielenberg, D. R., Samuel, S., Bose, D., Zhou, Y., Gray, M. J., Dallas, N. A., Fan, F., Xia, L., and Lu, J. (2009) Role of class 3 semaphorins and their receptors in tumor growth and angiogenesis. Clinical Cancer Research 15, 6763-6770 53. Lu, T.-P., Tsai, M.-H., Lee, J.-M., Hsu, C.-P., Chen, P.-C., Lin, C.-W., Shih, J.-Y., Yang, P.-C., Hsiao, C. K., Lai, L.-C., and Chuang, E. Y. (2010) Identification of a Novel Biomarker, <em>SEMA5A</em>, for Non–Small Cell Lung Carcinoma in Nonsmoking Women. Cancer Epidemiology Biomarkers & Prevention 19, 2590-2597 54. Varshavsky, A., Kessler, O., Abramovitch, S., Kigel, B., Zaffryar, S., Akiri, G., and Neufeld, G. (2008) Semaphorin-3B is an angiogenesis inhibitor that is inactivated by furin-like pro-protein convertases. Cancer Research 68, 6922-6931 55. Maione, F., Molla, F., Meda, C., Latini, R., Zentilin, L., Giacca, M., Seano, G., Serini, G., Bussolino, F., and Giraudo, E. (2009) Semaphorin 3A is an endogenous angiogenesis inhibitor that blocks tumor growth and normalizes tumor vasculature in transgenic mouse models. The Journal of Clinical Investigation 119, 3356-3372 56. Casazza, A., Fu, X., Johansson, I., Capparuccia, L., Andersson, F., Giustacchini, A., Squadrito, M. L., Venneri, M. A., Mazzone, M., and Larsson, E. (2011) Systemic and targeted delivery of semaphorin 3A inhibits tumor angiogenesis and progression in mouse tumor models. Arteriosclerosis Thrombosis and Vascular Biology 31, 741-749 57. Potiron, V. A., Sharma, G., Nasarre, P., Clarhaut, J. A., Augustin, H. G., Gemmill, R. M., Roche, J., and Drabkin, H. A. (2007) Semaphorin SEMA3F affects multiple signaling pathways in lung cancer cells. Cancer Research 67, 8708-8715 58. Meyronet, D., Massoma, P., Thivolet, F., Chalabreysse, L., Rogemond, V., Schlama, A., Honnorat, J., and Thomasset, N. (2008) Extensive expression of collapsin response mediator protein 5 (CRMP5) is a specific marker of high-grade lung neuroendocrine carcinoma. The American journal of surgical pathology 32, 1699-1708 59. Nagai, H., Sugito, N., Matsubara, H., Tatematsu, Y., Hida, T., Sekido, Y., Nagino, M., Nimura, Y., Takahashi, T., and Osada, H. (2007) CLCP1 interacts with semaphorin 4B and regulates motility of lung cancer cells. Oncogene 26, 4025-4031 60. Neufeld, G., and Kessler, O. (2008) The semaphorins: versatile regulators of tumour progression and tumour angiogenesis. Nature Reviews Cancer 8, 632-645 61. Pasterkamp, R. J. (2012) Getting neural circuits into shape with semaphorins. Nature Reviews Neuroscience 13, 605-618 62. Urbich, C., Kaluza, D., Frömel, T., Knau, A., Bennewitz, K., Boon, R. A., Bonauer, A., Doebele, C., Boeckel, J.-N., and Hergenreider, E. (2012) MicroRNA-27a/b controls endothelial cell repulsion and angiogenesis by targeting semaphorin 6A. Blood 119, 1607-1616 63. Zhou, Q., Gallagher, R., Ufret-Vincenty, R., Li, X., Olson, E. N., and Wang, S. (2011) Regulation of angiogenesis and choroidal neovascularization by members of microRNA-23∼ 27∼ 24 clusters. Proceedings of the National Academy of Sciences 108, 8287-8292 64. Dhanabal, M., Wu, F., Alvarez, E., McQueeney, K. D., Jeffers, M., MacDougall, J., Boldog, F. L., Hackett, C., Shenoy, S., Khramtsov, N., Weiner, J., Lichenstein, H. S., and LaRochelle, W. J. (2005) Recombinant semaphorin 6A-1 ectodomain inhibits in vivo growth factor and tumor cell line-induced angiogenesis. Cancer biology & therapy 4, 659-668 65. Kerr, J. F., Wyllie, A. H., and Currie, A. R. (1972) Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics. British Journal of Cancer 26, 239 66. Adams, J., and Cory, S. (2007) The Bcl-2 apoptotic switch in cancer development and therapy. Oncogene 26, 1324-1337 67. Adams, J. M., and Cory, S. (2007) Bcl-2-regulated apoptosis: mechanism and therapeutic potential. Current Opinion in Immunology 19, 488-496 68. Czabotar, P. E., Lessene, G., Strasser, A., and Adams, J. M. (2014) Control of apoptosis by the BCL-2 protein family: implications for physiology and therapy. Nature reviews. Molecular cell biology 15, 49-63 69. Hotchkiss, R. S., Strasser, A., McDunn, J. E., and Swanson, P. E. (2009) Cell death. New England Journal of Medicine 361, 1570-1583 70. Kroemer, G., Galluzzi, L., Vandenabeele, P., Abrams, J., Alnemri, E., Baehrecke, E., Blagosklonny, M., El-Deiry, W., Golstein, P., and Green, D. (2009) Classification of cell death: recommendations of the Nomenclature Committee on Cell Death 2009. Cell Death & Differentiation 16, 3-11 71. Savill, J., Wyllie, A., Henson, J., Walport, M., Henson, P., and Haslett, C. (1989) Macrophage phagocytosis of aging neutrophils in inflammation. Programmed cell death in the neutrophil leads to its recognition by macrophages. Journal of Clinical Investigation 83, 865 72. Lawen, A. (2003) Apoptosis—an introduction. Bioessays 25, 888-896 73. Hanahan, D., and Weinberg, R. A. (2000) The hallmarks of cancer. Cell 100, 57-70 74. Shivapurkar, N., Reddy, J., Chaudhary, P. M., and Gazdar, A. F. (2003) Apoptosis and lung cancer: a review. Journal of Cellular Biochemistry 88, 885-898 75. Bremer, E., van Dam, G., Kroesen, B. J., de Leij, L., and Helfrich, W. (2006) Targeted induction of apoptosis for cancer therapy: current progress and prospects. Trends in Molecular Medicine 12, 382-393 76. Green, D. R., and Kroemer, G. (2004) The pathophysiology of mitochondrial cell death. Science 305, 626-629 77. Breckenridge, D. G., and Xue, D. (2004) Regulation of mitochondrial membrane permeabilization by BCL-2 family proteins and caspases. Current Opinion in Cell Biology 16, 647-652 78. Saelens, X., Festjens, N., Walle, L. V., Van Gurp, M., van Loo, G., and Vandenabeele, P. (2004) Toxic proteins released from mitochondria in cell death. Oncogene 23, 2861-2874 79. Du, C., Fang, M., Li, Y., Li, L., and Wang, X. (2000) Smac, a mitochondrial protein that promotes cytochrome c–dependent caspase activation by eliminating IAP inhibition. Cell 102, 33-42 80. Verhagen, A. M., Ekert, P. G., Pakusch, M., Silke, J., Connolly, L. M., Reid, G. E., Moritz, R. L., Simpson, R. J., and Vaux, D. L. (2000) Identification of DIABLO, a mammalian protein that promotes apoptosis by binding to and antagonizing IAP proteins. Cell 102, 43-53 81. Susin, S. A., Lorenzo, H. K., Zamzami, N., Marzo, I., Snow, B. E., Brothers, G. M., Mangion, J., Jacotot, E., Costantini, P., and Loeffler, M. (1999) Molecular characterization of mitochondrial apoptosis-inducing factor. Nature 397, 441-446 82. Li, L. Y., Luo, X., and Wang, X. (2001) Endonuclease G is an apoptotic DNase when released from mitochondria. Nature 412, 95-99 83. Ashkenazi, A., and Dixit, V. M. (1999) Apoptosis control by death and decoy receptors. Current Opinion in Cell Biology 11, 255-260 84. Li, H., Zhu, H., Xu, C.-j., and Yuan, J. (1998) Cleavage of BID by caspase 8 mediates the mitochondrial damage in the Fas pathway of apoptosis. Cell 94, 491-501 85. Luo, X., Budihardjo, I., Zou, H., Slaughter, C., and Wang, X. (1998) Bid, a Bcl2 interacting protein, mediates cytochrome c release from mitochondria in response to activation of cell surface death receptors. Cell 94, 481-490 86. Scaffidi, C., Fulda, S., Srinivasan, A., Friesen, C., Li, F., Tomaselli, K. J., Debatin, K. M., Krammer, P. H., and Peter, M. E. (1998) Two CD95 (APO‐1/Fas) signaling pathways. The EMBO journal 17, 1675-1687 87. Lavrik, I. N. (2010) Systems biology of apoptosis signaling networks. Current Opinion in Biotechnology 21, 551-555 88. Schleich, K., Krammer, P. H., and Lavrik, I. N. (2013) The chains of death: a new view on caspase-8 activation at the DISC. Cell Cycle 12, 193-194 89. Park, H. H., Lo, Y. C., Lin, S. C., Wang, L., Yang, J. K., and Wu, H. (2007) The death domain superfamily in intracellular signaling of apoptosis and inflammation. The Annual Review of Immunology 25, 561-586 90. Li, H., Wojtaszek, J. L., and Greene, L. H. (2009) Analysis of conservation in the Fas-associated death domain protein and the importance of conserved tryptophans in structure, stability and folding. Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics 1794, 583-593 91. Steward, A., McDowell, G. S., and Clarke, J. (2009) Topology is the principal determinant in the folding of a complex all-alpha Greek key death domain from human FADD. J. Mol. Biol. 389, 425-437 92. Weber, C. H., and Vincenz, C. (2001) The death domain superfamily: a tale of two interfaces? Trends Biochem. Sci. 26, 475-481 93. Kersse, K., Verspurten, J., Vanden Berghe, T., and Vandenabeele, P. (2011) The death-fold superfamily of homotypic interaction motifs. Trends Biochem. Sci. 36, 541-552 94. Chen, Z., Sangwan, V., Banerjee, S., Chugh, R., Dudeja, V., Vickers, S. M., and Saluja, A. K. (2014) Triptolide sensitizes pancreatic cancer cells to TRAIL-induced activation of the death receptor pathway. Cancer Lett. 348, 156-166 95. Chang, W. A., Lin, E. S., Tsai, M. J., Huang, M. S., and Kuo, P. L. (2014) Isolinderalactone inhibits proliferation of A549 human nonsmall cell lung cancer cells by arresting the cell cycle at the G0/G1 phase and inducing a Fas receptor and soluble Fas ligand-mediated apoptotic pathway. Molecular medicine reports 9, 1653-1659 96. Reap, E. A., Roof, K., Maynor, K., Borrero, M., Booker, J., and Cohen, P. L. (1997) Radiation and stress-induced apoptosis: A role for Fas/Fas ligand interactions. Proceedings of the National Academy of Sciences 94, 5750-5755 97. Kim, P. K., Weller, R., Hua, Y., and Billiar, T. R. (2003) Ultraviolet irradiation increases FADD protein in apoptotic human keratinocytes. Biochemical and Biophysical Research Communications 302, 290-295 98. Yang, X., Boehm, J. S., Yang, X., Salehi-Ashtiani, K., Hao, T., Shen, Y., Lubonja, R., Thomas, S. R., Alkan, O., Bhimdi, T., Green, T. M., Johannessen, C. M., Silver, S. J., Nguyen, C., Murray, R. R., Hieronymus, H., Balcha, D., Fan, C., Lin, C., Ghamsari, L., Vidal, M., Hahn, W. C., Hill, D. E., and Root, D. E. (2011) A public genome-scale lentiviral expression library of human ORFs. Nat. Methods 8, 659-661 99. Wang, J., Li, W., Min, J., Ou, Q., and Chen, J. (2003) Fas siRNA reduces apoptotic cell death of allogeneic-transplanted hepatocytes in mouse spleen. Transplantation proceedings 35, 1594-1595 100. Perl, M., Chung, C.-S., Lomas-Neira, J., Rachel, T.-M., Biffl, W. L., Cioffi, W. G., and Ayala, A. (2005) Silencing of Fas, but not caspase-8, in lung epithelial cells ameliorates pulmonary apoptosis, inflammation, and neutrophil influx after hemorrhagic shock and sepsis. The American Journal of Pathology 167, 1545-1559 101. Reed, J. C. (2000) Mechanisms of apoptosis. The American Journal of Pathology 157, 1415-1430 102. Thomas, L. R., Johnson, R. L., Reed, J. C., and Thorburn, A. (2004) The C-terminal tails of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and Fas receptors have opposing functions in Fas-associated death domain (FADD) recruitment and can regulate agonist-specific mechanisms of receptor activation. The Journal of biological chemistry 279, 52479-52486 103. Grimm, S., Stanger, B. Z., and Leder, P. (1996) RIP and FADD: two 'death domain'-containing proteins can induce apoptosis by convergent, but dissociable, pathways. Proceedings of The National Academy of Sciences 93, 10923-10927 104. Chen, G., Bhojani, M. S., Heaford, A. C., Chang, D. C., Laxman, B., Thomas, D. G., Griffin, L. B., Yu, J., Coppola, J. M., Giordano, T. J., Lin, L., Adams, D., Orringer, M. B., Ross, B. D., Beer, D. G., and Rehemtulla, A. (2005) Phosphorylated FADD induces NF-κB, perturbs cell cycle, and is associated with poor outcome in lung adenocarcinomas. Proceedings of The National Academy of Sciences 102, 12507-12512 105. Sheikh, M. S., and Huang, Y. (2003) The FADD is going nuclear. Cell Cycle 2, 346-347 106. Shimada, K., Matsuyoshi, S., Nakamura, M., Ishida, E., and Konishi, N. (2005) Phosphorylation status of Fas-associated death domain-containing protein (FADD) is associated with prostate cancer progression. The Journal of Pathology 206, 423-432 107. Nogi, T., Yasui, N., Mihara, E., Matsunaga, Y., Noda, M., Yamashita, N., Toyofuku, T., Uchiyama, S., Goshima, Y., Kumanogoh, A., and Takagi, J. (2010) Structural basis for semaphorin signalling through the plexin receptor. Nature 467, 1123-1127 108. Gras, C., Eiz‐Vesper, B., Jaimes, Y., Immenschuh, S., Jacobs, R., Witte, T., Blasczyk, R., and Figueiredo, C. (2014) Secreted semaphorin 5A activates immune effector cells and is a biomarker for rheumatoid arthritis. Arthritis & Rheumatology 66, 1461-1471 | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/59823 | - |
dc.description.abstract | 在台灣,肺癌是所有癌症中致死率最高的。目前治療肺癌的方式主要是透過化學療法和放射療法,但是這些治療方式皆會產生嚴重的副作用。從本實驗室先前研究中發現肺癌細胞的Semaphorin 6A (SEMA6A) 蛋白表現量比正常肺細胞來的低,並且將SEMA6A大量表現在肺癌細胞株中, SEMA6A 會誘發細胞凋亡。因此本研究在探討SEMA6A是否會透過與死亡受體 (Death receptor) 交互作用,啟動細胞凋亡訊號傳遞,造成肺癌細胞死亡。實驗結果顯示在 H1299 肺癌細胞株中,當FAS,死亡受體5或腫瘤壞死因數受體1等死亡受體在被抑制的情況下,表現 SEMA6A 細胞質片段仍會誘發細胞凋亡,同時在實驗室先前研究中發現,FADD在被抑制的情況下,SEMA6A 細胞質片段誘發的細胞凋亡會減少。顯示SEMA6A 並不是與死亡受體交互作用,而主要是透過與 FADD 交互作用誘導細胞凋亡。本篇研究深入探討SEMA6A與 FADD 結合區域。在 HEK293T 細胞株中大量表現不同的 SEMA6A 刪減系列蛋白,進而觀察SEMA6A與 FADD 結合能力,誘發的細胞凋亡以及細胞凋亡標記蛋白 caspase-8的活化情形。實驗結果顯示在 SEMA6A蛋白中的第897~906 胺基酸處的α-螺旋是調控細胞凋亡的重要區域,此外927~1031 胺基酸區域中亦含有調控細胞凋亡的重要區域。瞭解 SEMA6A和FADD 的交互作用區域後,進一步分析 SEMA6A 其他domain之作用後發現,SEMA6A膜外的 SEMA domain會減少SEMA6A細胞質片段與 FADD 的交互作用,進而降低細胞凋亡。因此,我們接著探討SEMA domain是否可以透過影響SEMA6A 與FADD的交互作用,抑制正常細胞中放射線或化療藥物治療所活化的 FADD 凋亡訊號進而導致的細胞凋亡,而達到減低副作用的功能。因此利用管柱層析純化出SEMA domain蛋白,並利用有內生性SEMA6A 蛋白表現的神經膠瘤細胞株M059K 進行實驗。細胞先處理SEMA domain蛋白後,再處理化療藥物 Cisplatin或放射線,觀察外加的SEMA domain蛋白是否可以降低Cisplatin或放射線誘發的細胞毒性。初步的實驗結果顯示,在處理 Cisplatin或照射放射線後,SEMA domain對於細胞的生長、凋亡以及存活情形在統計上沒有呈現顯著的差異。因此 SEMA domain 對於降低化療藥物或是放射線誘發的細胞毒性上的應用仍須更多研究。 | zh_TW |
dc.description.abstract | In Taiwan, the lung cancer has the highest mortality rate in all cancers. Although chemotherapy and radiation therapy are the main treatments of lung cancer, these therapies usually induce severe side effects. Our previous research has shown that the levels of Semaphorin 6A (SEMA6A) were lower in the lung cancer tissues than in the adjacent normal tissues. Furthermore, we overexpressed SEMA6A in the lung cancer cells and demonstrated that the cytoplasmic region of SEMA6A could interact with FADD to induce apoptosis. In the present research, we were aiming to study if SEMA6A could interact with death receptors (DRs) to activate apoptotic signaling. Our data showed that the overexpression of the cytoplasmic domain of SEMA6A could promote apoptosis in H1299 following down-regulation of DRs including FAS, DR5 and TNFR1. In the meantime, we have found that silencing of FADD inhibits cytoplasmic domain of SEMA6A induced apoptosis. It suggests that SEMA6A induces apoptosis through the interaction with FADD rather than with DRs. To map the binding region of FADD on SEMA6A, we overexpressed a series of deletion constructs of SEMA6A in HEK293T cells. Then, we determined the cell proliferation, apoptosis rate, and the level of cleaved caspase-8. Our results reveal that the α-helix locating on amino acids 897-906 of SEMA6A and the amino acids 927-1031 of SEMA6A are critical in the regulation of SEMA6A-induced apoptosis. After understanding the interaction region of FADD and SEMA6A, we further analyzed the functions of different domains of SEMA6A. The results indicated that the extracellular domain could reduce apoptosis by suppressing the interaction between the FADD and the intracellular domain of SEMA6A. We subsequently study if the extracellular domain of SEMA6A could reduce the side effect of chemotherapy or radiation therapy by interacting with endogenous SEMA6A to inhibit irradiation or Cisplatin (chemotherapy drug) induced FADD-dependent death signaling in normal lung cells. Therefore, we purified the extracellular domain of SEMA6A by affinity chromatography, and selected M059K, the cell line with the endogenous expression of SEMA6A, for the further study. The M059K cells were cultured with the extracellular domain of SEMA6A followed by the treatments of irradiation or Cisplatin. The results showed that the proliferation, apoptosis and survival were no significant difference between M059K cells cultured with and without the extracellular domain of SEMA6A. Therefore, the further study is still needed to elucidate the application of SEMA domain in the reduction of chemotherapy drugs or radiation-induced cytotoxicity. | en |
dc.description.provenance | Made available in DSpace on 2021-06-16T09:39:49Z (GMT). No. of bitstreams: 1 ntu-106-R02b21035-1.pdf: 2510673 bytes, checksum: 0c29a5f387dbb1fb07e42ded2bd2f185 (MD5) Previous issue date: 2017 | en |
dc.description.tableofcontents | 致謝 I
中文摘要 II Abstract IV 目錄 VI 圖目錄 VIII 第一章 序論 1 1-1 肺癌 1 1-1-1 肺癌介紹 1 1-1-2 放射線治療 2 1-1-3 化學治療 4 1-2 Semaphorins 5 1-2-1 Semaphorins的介紹 5 1-2-2 Semaphorins和受體 6 1-2-3 Semaphorins主導的訊號傳遞路徑 6 1-2-4 Semaphorins蛋白與肺癌 7 1-2-5 Semaphorin 6A與肺癌 8 1-3 細胞凋亡 8 1-3-1 細胞凋亡介紹 8 1-3-2 細胞凋亡和癌症 9 1-3-3 細胞凋亡路徑 (Apoptosis pathway) 9 1-3-4 死亡受體 (Death receptors) 11 1-3-5 死亡摺疊結構域 (Death fold domain) 12 第二章研究動機 14 第三章實驗與方法 15 3-1 質體重組建構 15 3-2細胞培養 19 3-3分析蛋白質的表現 21 3-4分析RNA的表現 24 3-5慢病毒包裝系統 (lentivirus packaging system) 26 3-6過渡性轉染 (transient transfection) 28 3-7免疫共沉澱法 (Co-Immunopreciptation) 28 3-8細胞增生試驗 (MTT assay) 29 3-9 HIS-SEMA domain重組蛋白的純化 29 3-10細胞凋亡 (apoptosis) 分析 30 3-11 統計方法 30 第四章結果 31 4-1 探討semaphorin 6A跟死亡受體 (death receptors) 的相關性 31 4-2 探討Semaphorin 6A跟FADD結合位置 32 4-3 Sema domain對 Cisplatin 處理細胞株對細胞生長或凋亡的影響 35 第五章討論與限制 38 5-1 探討利用慢病毒包裝系統在TC1 deletion constructs誘導細胞凋亡上的限制 38 5-2探討FAS的下調控後大量表現TC4對細胞凋亡的影響 38 5-3探討Semaphorin 6A的細胞質區域與FADD交互作用 39 5-4探討SEMA domain應用在處理Cisplatin或放射線的細胞實驗 41 第六章結論與未來研究 41 參考文獻 57 | |
dc.language.iso | zh-TW | |
dc.title | 探討 Semaphorin 6A 與 FADD 之交互作用及其應用於肺癌治療上之潛力 | zh_TW |
dc.title | To study the interactions between FADD and Semaphorin 6A and its potential applications to lung cancer therapy | en |
dc.type | Thesis | |
dc.date.schoolyear | 105-1 | |
dc.description.degree | 碩士 | |
dc.contributor.coadvisor | 蔡孟勳(Mong-Hsun Tsai) | |
dc.contributor.oralexamcommittee | 李心予(Hsin-yu Lee),賴亮全(Liang-Chuan, Lai),盧子彬(Tzu-Pin Lu) | |
dc.subject.keyword | Semaphorin 6A,FADD,細胞凋亡,Death receptors,肺癌, | zh_TW |
dc.subject.keyword | Semaphorin 6A,FADD,apoptosis,death receptors,lung cancer, | en |
dc.relation.page | 67 | |
dc.identifier.doi | 10.6342/NTU201700315 | |
dc.rights.note | 有償授權 | |
dc.date.accepted | 2017-02-08 | |
dc.contributor.author-college | 生命科學院 | zh_TW |
dc.contributor.author-dept | 生命科學系 | zh_TW |
顯示於系所單位: | 生命科學系 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-106-1.pdf 目前未授權公開取用 | 2.45 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。